Skip to main content
SpringerLink
Log in
Book cover

Gynecological Cancers pp 151–166Cite as

Racial/Ethnic Disparities in Gynecological Cancer Screening, Treatment, and Survival

  • Chapter
  • First Online:

  • 806 Accesses

Part of the book series: Current Clinical Oncology ((CCO))

Abstract

Differences in cancer screening and treatment have been associated with race and ethnic classification. Several disparities have been identified in gynecologic cancer screening and therapy, most often affecting black and Hispanic women. The causes of health disparities are multifactorial and involve systemic, provider, and patient factors, including cultural attitudes, socioeconomic status, education level, and geographic barriers. This chapter documents the disparities in gynecologic cancer screening, treatment, and survival for women with cancers of the cervix, uterus, ovaries, vagina, and vulva. Each disease site has specific areas where minimizing differences in access to care can potentially minimize the disparate health outcomes seen among specific racial and ethnic groups.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   139.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. NAACCR Race and Ethnicity Work Group. NAACCR guideline for enhancing Hispanic/Latino Identification: Revised NAACCR Hispanic/Latino identification algorithm [NHIA v2.2.1] Springfield, IL; September 2011 http://www.naaccr org/Research/DataAnalysisTools aspx.

  2. American Cancer Society. Cancer facts & figures 2015. Atlanta 2015.

    Google Scholar 

  3. Surveillance EaERSP. SEER*Stat Database: NAACCR incidence – CiNA analytic file, 1995–2009, North American Association of Central Cancer Registries.

    Google Scholar 

  4. Jemal A, Simard EP, Dorell C, Noone AM, Markowitz LE, Kohler B, et al. Annual report to the nation on the status of cancer, 1975–2009, featuring the burden and trends in human papillomavirus(HPV)-associated cancers and HPV vaccination coverage levels. J Natl Cancer Inst. 2013;105(3):175–201.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Simard EP, Naishadham D, Saslow D, Jemal A. Age-specific trends in black-white disparities in cervical cancer incidence in the United States: 1975–2009. Gynecol Oncol. 2012;127(3):611–5.

    Article  PubMed  Google Scholar 

  6. American Cancer Society. Cancer facts & figures for Hispanics/Latinos 2012–2014. Atlanta 2012.

    Google Scholar 

  7. Watson M, Saraiya M, Benard V, Coughlin SS, Flowers L, Cokkinides V, et al. Burden of cervical cancer in the United States, 1998–2003. Cancer. 2008;113(10 Suppl):2855–64.

    Article  PubMed  Google Scholar 

  8. American Cancer Society. Cancer facts & figures for African Americans 2013–2014. Atlanta 2013.

    Google Scholar 

  9. Smith RA, Cokkinides V, Brooks D, Saslow D, Shah M, Brawley OW. Cancer screening in the United States, 2011: a review of current American Cancer Society guidelines and issues in cancer screening. CA Cancer J Clin. 2011;61(1):8–30.

    Article  PubMed  Google Scholar 

  10. Centers for Disease Control and Prevention. Chartbook on trends in the health of Americans 2010. Hyattsville, MD: National Center for Health Statistics; 2010.

    Google Scholar 

  11. American Cancer Society. Cancer prevention and early detection facts and figures 2012. Atlanta, GA2012.

    Google Scholar 

  12. Benard VB, Lawson HW, Eheman CR, Anderson C, Helsel W. Adherence to guidelines for follow-up of low-grade cytologic abnormalities among medically underserved women. Obstet Gynecol. 2005;105(6):1323–8.

    Article  PubMed  Google Scholar 

  13. Satterwhite CL, Torrone E, Meites E, Dunne EF, Mahajan R, Ocfemia MC, et al. Sexually transmitted infections among US women and men: prevalence and incidence estimates, 2008. Sex Transm Dis. 2013;40(3):187–93.

    Article  PubMed  Google Scholar 

  14. Weinstock H, Berman S, Cates W. Sexually transmitted diseases among American youth: incidence and prevalence estimates, 2000. Perspect Sex Reprod Health. 2004;36(1):6–10.

    Article  PubMed  Google Scholar 

  15. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med. 1998;338(7):423–8.

    Article  CAS  PubMed  Google Scholar 

  16. Hariri S, Unger ER, Sternberg M, Dunne EF, Swan D, Patel S, et al. Prevalence of genital human papillomavirus among females in the United States, the National Health And Nutrition Examination Survey, 2003–2006. J Infect Dis. 2011;204(4):566–73.

    Article  PubMed  Google Scholar 

  17. Dunne EF, Unger ER, Sternberg M, McQuillan G, Swan DC, Patel SS, et al. Prevalence of HPV infection among females in the United States. JAMA. 2007;297(8):813–9.

    Article  CAS  PubMed  Google Scholar 

  18. Giuliano AR, Papenfuss M, Schneider A, Nour M, Hatch K. Risk factors for high-risk type human papillomavirus infection among Mexican-American women. Cancer Epidemiol Biomarkers Prev. 1999;8(7):615–20.

    CAS  PubMed  Google Scholar 

  19. Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 2005;6(5):271–8.

    Article  PubMed  Google Scholar 

  20. Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007;356(19):1928–43.

    Article  CAS  PubMed  Google Scholar 

  21. Future II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007;356(19):1915–27.

    Article  Google Scholar 

  22. Paavonen J, Naud P, Salmerón J, Wheeler CM, Chow SN, Apter D, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet. 2009;374(9686):301–14.

    Article  CAS  PubMed  Google Scholar 

  23. Paavonen J, Jenkins D, Bosch FX, Naud P, Salmerón J, Wheeler CM, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet. 2007;369(9580):2161–70.

    Article  CAS  PubMed  Google Scholar 

  24. Markowitz LE, Dunne EF, Saraiya M, Chesson HW, Curtis CR, Gee J, et al. Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2014;63(RR-05):1–30.

    PubMed  Google Scholar 

  25. NIS-Teen. Vaccination coverage among adolescents aged 13–17 years—United States, 2012. 2012. http://www.cdc.gov/vaccines/stats-surv/nisteen/data/tables_2012.htm.

  26. Jeudin P, Liveright E, Del Carmen MG, Perkins RB. Race, ethnicity, and income factors impacting human papillomavirus vaccination rates. Clin Ther. 2014;36(1):24–37.

    Article  PubMed  Google Scholar 

  27. Williams WW, Lu PJ, O'Halloran A, Bridges CB, Pilishvili T, Hales CM, et al. Noninfluenza vaccination coverage among adults – United States, 2012. MMWR Morb Mortal Wkly Rep. 2014;63(5):95–102.

    PubMed  Google Scholar 

  28. Hamlish T, Clarke L, Alexander KA. Barriers to HPV immunization for African American adolescent females. Vaccine. 2012;30(45):6472–6.

    Article  PubMed  Google Scholar 

  29. WingroveFreeman HP, Wingrove WB. Excess cervical cancer mortality: a marker for low access to health care in poor communities. NIH Pub. No. 05–5282. ed. Rockville, MD: National Cancer Institute, Center to Reduce Cancer Health Disparities; 2005.

    Google Scholar 

  30. Brookfield KF, Cheung MC, Lucci J, Fleming LE, Koniaris LG. Disparities in survival among women with invasive cervical cancer: a problem of access to care. Cancer. 2009;115(1):166–78.

    Article  PubMed  Google Scholar 

  31. Rauh-Hain JA, Clemmer JT, Bradford LS, Clark RM, Growdon WB, Goodman A, et al. Racial disparities in cervical cancer survival over time. Cancer. 2013;119(20):3644–52.

    Article  PubMed  Google Scholar 

  32. Fleming S, Schluterman NH, Tracy JK, Temkin SM. Black and white women in Maryland receive different treatment for cervical cancer. PLoS One. 2014;9(8), e104344.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Farley JH, Hines JF, Taylor RR, Carlson JW, Parker MF, Kost ER, et al. Equal care ensures equal survival for African-American women with cervical carcinoma. Cancer. 2001;91(4):869–73.

    Article  CAS  PubMed  Google Scholar 

  34. Benard VB, Howe W, Royalty J, Helsel W, Kammerer W, Richardson LC. Timeliness of cervical cancer diagnosis and initiation of treatment in the National Breast and Cervical Cancer Early Detection Program. J Womens Health (Larchmt). 2012;21(7):776–82.

    Article  Google Scholar 

  35. Horner MJ, Altekruse SF, Zou Z, Wideroff L, Katki HA, Stinchcomb DG. U.S. geographic distribution of prevaccine era cervical cancer screening, incidence, stage, and mortality. Cancer Epidemiol Biomarkers Prev. 2011;20(4):591–9.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277–300.

    Article  PubMed  Google Scholar 

  37. Centers for Disease Control and Prevention. Uterine cancer rates by race and ethnicity. 27 Aug 2014. http://www.cdc.gov/cancer/uterine/statistics/race.htm.

  38. Sherman ME, Devesa SS. Analysis of racial differences in incidence, survival, and mortality for malignant tumors of the uterine corpus. Cancer. 2003;98(1):176–86.

    Article  PubMed  Google Scholar 

  39. Setiawan VW, Pike MC, Kolonel LN, Nomura AM, Goodman MT, Henderson BE. Racial/ethnic differences in endometrial cancer risk: the multiethnic cohort study. Am J Epidemiol. 2007;165(3):262–70.

    Article  PubMed  Google Scholar 

  40. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58(2):71–96.

    Article  PubMed  Google Scholar 

  41. Hicks ML, Phillips JL, Parham G, Andrews N, Jones WB, Shingleton HM, et al. The National Cancer Data Base report on endometrial carcinoma in African-American women. Cancer. 1998;83(12):2629–37.

    Article  CAS  PubMed  Google Scholar 

  42. Wright JD, Fiorelli J, Schiff PB, Burke WM, Kansler AL, Cohen CJ, et al. Racial disparities for uterine corpus tumors: changes in clinical characteristics and treatment over time. Cancer. 2009;115(6):1276–85.

    Article  PubMed  Google Scholar 

  43. Smotkin D, Nevadunsky NS, Harris K, Einstein MH, Yu Y, Goldberg GL. Histopathologic differences account for racial disparity in uterine cancer survival. Gynecol Oncol. 2012;127(3):616–9.

    Article  PubMed  Google Scholar 

  44. Oliver KE, Enewold LR, Zhu K, Conrads TP, Rose GS, Maxwell GL, et al. Racial disparities in histopathologic characteristics of uterine cancer are present in older, not younger blacks in an equal-access environment. Gynecol Oncol. 2011;123(1):76–81.

    Article  PubMed  Google Scholar 

  45. Cook LS, Nelson HE, Cockburn M, Olson SH, Muller CY, Wiggins CL. Comorbidities and endometrial cancer survival in Hispanics and non-Hispanic whites. Cancer Causes Control. 2013;24(1):61–9.

    Article  PubMed  Google Scholar 

  46. Rodriguez AM, Schmeler KM, Kuo YF. Disparities in endometrial cancer outcomes between non-Hispanic white and Hispanic women. Gynecol Oncol. 2014;135(3):525–33.

    Article  PubMed  Google Scholar 

  47. Díaz-Montes TP, Alberg A, Zahurak ML, Trimble EL, Bristow RE. Cancer of the uterine corpus among Hispanic women living in the United States: patterns of staging, diagnosis, and primary treatment. Gynecol Oncol. 2005;96(3):753–9.

    Article  PubMed  Google Scholar 

  48. Mahdi H, Hou H, Kowk LL, Moslemi-Kebria M, Michener C. Type II endometrial cancer in Hispanic women: tumor characteristics, treatment and survival compared to non-Hispanic white women. Gynecol Oncol. 2014;133(3):512–7.

    Article  PubMed  Google Scholar 

  49. Risinger JI, Hayes K, Maxwell GL, Carney ME, Dodge RK, Barrett JC, et al. PTEN mutation in endometrial cancers is associated with favorable clinical and pathologic characteristics. Clin Cancer Res. 1998;4(12):3005–10.

    CAS  PubMed  Google Scholar 

  50. Maxwell GL, Risinger JI, Gumbs C, Shaw H, Bentley RC, Barrett JC, et al. Mutation of the PTEN tumor suppressor gene in endometrial hyperplasias. Cancer Res. 1998;58(12):2500–3.

    CAS  PubMed  Google Scholar 

  51. Maxwell GL, Risinger JI, Alvarez AA, Barrett JC, Berchuck A. Favorable survival associated with microsatellite instability in endometrioid endometrial cancers. Obstet Gynecol. 2001;97(3):417–22.

    CAS  PubMed  Google Scholar 

  52. Maxwell GL, Risinger JI, Hayes KA, Alvarez AA, Dodge RK, Barrett JC, et al. Racial disparity in the frequency of PTEN mutations, but not microsatellite instability, in advanced endometrial cancers. Clin Cancer Res. 2000;6(8):2999–3005.

    CAS  PubMed  Google Scholar 

  53. Kohler MF, Carney P, Dodge R, Soper JT, Clarke-Pearson DL, Marks JR, et al. p53 overexpression in advanced-stage endometrial adenocarcinoma. Am J Obstet Gynecol. 1996;175(5):1246–52.

    Article  CAS  PubMed  Google Scholar 

  54. Clifford SL, Kaminetsky CP, Cirisano FD, Dodge R, Soper JT, Clarke-Pearson DL, et al. Racial disparity in overexpression of the p53 tumor suppressor gene in stage I endometrial cancer. Am J Obstet Gynecol. 1997;176(6):S229–32.

    Article  CAS  PubMed  Google Scholar 

  55. Alkushi A, Lim P, Coldman A, Huntsman D, Miller D, Gilks CB. Interpretation of p53 immunoreactivity in endometrial carcinoma: establishing a clinically relevant cut-off level. Int J Gynecol Pathol. 2004;23(2):129–37.

    Article  PubMed  Google Scholar 

  56. Santin AD, Bellone S, Siegel ER, Palmieri M, Thomas M, Cannon MJ, et al. Racial differences in the overexpression of epidermal growth factor type II receptor (HER2/neu): a major prognostic indicator in uterine serous papillary cancer. Am J Obstet Gynecol. 2005;192(3):813–8.

    Article  CAS  PubMed  Google Scholar 

  57. Ferguson SE, Olshen AB, Levine DA, Viale A, Barakat RR, Boyd J. Molecular profiling of endometrial cancers from African-American and Caucasian women. Gynecol Oncol. 2006;101(2):209–13.

    Article  CAS  PubMed  Google Scholar 

  58. De Vivo I, Prescott J, Setiawan VW, Olson SH, Wentzensen N, Attia J, et al. Genome-wide association study of endometrial cancer in E2C2. Hum Genet. 2014;133(2):211–24.

    Article  PubMed  Google Scholar 

  59. Setiawan VW, Schumacher F, Prescott J, Haessler J, Malinowski J, Wentzensen N, et al. Cross-cancer pleiotropic analysis of endometrial cancer: PAGE and E2C2 consortia. Carcinogenesis. 2014;35(9):2068–73.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Farley J, Risinger JI, Rose GS, Maxwell GL. Racial disparities in blacks with gynecologic cancers. Cancer. 2007;110(2):234–43.

    Article  PubMed  Google Scholar 

  61. Madison T, Schottenfeld D, James SA, Schwartz AG, Gruber SB. Endometrial cancer: socioeconomic status and racial/ethnic differences in stage at diagnosis, treatment, and survival. Am J Public Health. 2004;94(12):2104–11.

    Article  PubMed  PubMed Central  Google Scholar 

  62. Rauh-Hain JA, Buskwofie A, Clemmer J, Boruta DM, Schorge JO, Del-Carmen MG. Racial disparities in treatment of high-grade endometrial cancer in the medicare population. Obstet Gynecol. 2015;125(4):843–51.

    Article  PubMed  Google Scholar 

  63. Trimble EL, Harlan LC, Clegg LX, Stevens JL. Pre-operative imaging, surgery and adjuvant therapy for women diagnosed with cancer of the corpus uteri in community practice in the United States. Gynecol Oncol. 2005;96(3):741–8.

    Article  PubMed  Google Scholar 

  64. Fleury AC, Ibeanu OA, Bristow RE. Racial disparities in surgical care for uterine cancer. Gynecol Oncol. 2011;121(3):571–6.

    Article  CAS  PubMed  Google Scholar 

  65. Farley JH, Tian C, Rose GS, Brown CL, Birrer M, Risinger JI, et al. Chemotherapy intensity and toxicity among black and white women with advanced and recurrent endometrial cancer: a Gynecologic Oncology Group Study. Cancer. 2010;116(2):355–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. Fedewa SA, Lerro C, Chase D, Ward EM. Insurance status and racial differences in uterine cancer survival: a study of patients in the National Cancer Database. Gynecol Oncol. 2011;122(1):63–8.

    Article  CAS  PubMed  Google Scholar 

  67. Ko EM, Walter P, Clark L, Jackson A, Franasiak J, Bolac C, et al. The complex triad of obesity, diabetes and race in type I and II endometrial cancers: prevalence and prognostic significance. Gynecol Oncol. 2014;133(1):28–32.

    Article  PubMed  Google Scholar 

  68. Olson SH, Atoria CL, Cote ML, Cook LS, Rastogi R, Soslow RA, et al. The impact of race and comorbidity on survival in endometrial cancer. Cancer Epidemiol Biomarkers Prev. 2012;21(5):753–60.

    Article  PubMed  Google Scholar 

  69. Bristow RE, Palis BE, Chi DS, Cliby WA. The National Cancer Database report on advanced-stage epithelial ovarian cancer: impact of hospital surgical case volume on overall survival and surgical treatment paradigm. Gynecol Oncol. 2010;118:262–7.

    Article  PubMed  Google Scholar 

  70. Mercado C, Zingmond D, Karlan BY, Sekaris E, Gross J, Maggard-Gibbons M, et al. Quality of care in advanced ovarian cancer: the importance of provider specialty. Gynecol Oncol. 2010;117:18–22.

    Article  PubMed  Google Scholar 

  71. Kumpulainen S, Sankila R, Leminen A, Kuoppala T, Komulainen M, Puistola U, et al. The effect of hospital operative volume, residual tumor and first-line chemotherapy on survival of ovarian cancer – a prospective nation-wide study in Finland. Gynecol Oncol. 2009;115:199–203.

    Article  PubMed  Google Scholar 

  72. Elit L, Bondy SJ, Paszat L, Przybysz R, Levine M. Outcomes in surgery for ovarian cancer. Gynecol Oncol. 2002;87:260–7.

    Article  CAS  PubMed  Google Scholar 

  73. Bristow RE, Powell MA, Al-Hammadi N, Chen L, Miller JP, Roland PY, et al. Disparities in ovarian cancer care quality and survival according to race and socioeconomic status. J Natl Cancer Inst. 2013;105(11):823–32.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  74. Chornokur G, Amankwah EK, Schildkraut JM, Phelan CM. Global ovarian cancer health disparities. Gynecol Oncol. 2013;129(1):258–64.

    Article  PubMed  Google Scholar 

  75. Chase DM, Fedewa S, Chou TS, Chen A, Ward E, Brewster WR. Disparities in the allocation of treatment in advanced ovarian cancer: are there certain patient characteristics associated with nonstandard therapy? Obstet Gynecol. 2012;119:68–77.

    Article  PubMed  Google Scholar 

  76. Edwards BK, Noone AM, Mariotto AB, Simard EP, Boscoe FP, Henley SJ, et al. Annual report to the Nation on the status of cancer, 1975–2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer. Cancer. 2014;120(9):1290–314.

    Article  PubMed  Google Scholar 

  77. Morris CR, Sands MT, Smith LH. Ovarian cancer: predictors of early-stage diagnosis. Cancer Causes Control. 2010;21(8):1203–11.

    Article  PubMed  Google Scholar 

  78. Moorman PG, Palmieri RT, Akushevich L, Berchuck A, Schildkraut JM. Ovarian cancer risk factors in African-American and white women. Am J Epidemiol. 2009;170(5):598–606.

    Article  PubMed  PubMed Central  Google Scholar 

  79. Parham G, Phillips JL, Hicks ML, Andrews N, Jones WB, Shingleton HM, et al. The National Cancer Data Base report on malignant epithelial ovarian carcinoma in African-American women. Cancer. 1997;80(4):816–26.

    Article  CAS  PubMed  Google Scholar 

  80. Chan JK, Zhang M, Hu JM, Shin JY, Osann K, Kapp DS. Racial disparities in surgical treatment and survival of epithelial ovarian cancer in United States. J Surg Oncol. 2008;97(2):103–7.

    Article  PubMed  Google Scholar 

  81. Buys SS, Partridge E, Black A, Johnson CC, Lamerato L, Isaacs C, et al. Effect of screening on ovarian cancer mortality: the prostate, lung, colorectal and ovarian (PLCO) cancer screening randomized controlled trial. JAMA. 2011;305(22):2295–303.

    Article  CAS  PubMed  Google Scholar 

  82. Armstrong K, Micco E, Carney A, Stopfer J, Putt M. Racial differences in the use of BRCA1/2 testing among women with a family history of breast or ovarian cancer. JAMA. 2005;293(14):1729–36.

    Article  CAS  PubMed  Google Scholar 

  83. Pagán JA, Su D, Li L, Armstrong K, Asch DA. Racial and ethnic disparities in awareness of genetic testing for cancer risk. Am J Prev Med. 2009;37(6):524–30.

    Article  PubMed  Google Scholar 

  84. Olaya W, Esquivel P, Wong JH, Morgan JW, Freeberg A, Roy-Chowdhury S, et al. Disparities in BRCA testing: when insurance coverage is not a barrier. Am J Surg. 2009;198(4):562–5.

    Article  PubMed  Google Scholar 

  85. Levy DE, Byfield SD, Comstock CB, Garber JE, Syngal S, Crown WH, et al. Underutilization of BRCA1/2 testing to guide breast cancer treatment: black and Hispanic women particularly at risk. Genet Med. 2011;13(4):349–55.

    Article  PubMed  PubMed Central  Google Scholar 

  86. Schildkraut JM, Murphy SK, Palmieri RT, Iversen E, Moorman PG, Huang Z, et al. Trinucleotide repeat polymorphisms in the androgen receptor gene and risk of ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2007;16(3):473–80.

    Article  CAS  PubMed  Google Scholar 

  87. Schildkraut JM, Goode EL, Clyde MA, Iversen ES, Moorman PG, Berchuck A, et al. Single nucleotide polymorphisms in the TP53 region and susceptibility to invasive epithelial ovarian cancer. Cancer Res. 2009;69(6):2349–57.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  88. Vernooij F, Heintz P, Witteveen E, van der Graaf Y. The outcomes of ovarian cancer treatment are better when provided by gynecologic oncologists and in specialized hospitals: a systematic review. Gynecol Oncol. 2007;105(3):801–12.

    Article  PubMed  Google Scholar 

  89. Aranda MA, McGory M, Sekeris E, Maggard M, Ko C, Zingmond DS. Do racial/ethnic disparities exist in the utilization of high-volume surgeons for women with ovarian cancer? Gynecol Oncol. 2008;111:166–72.

    Article  PubMed  PubMed Central  Google Scholar 

  90. Bristow RE, Ueda S, Gerardi MA, Ajiboye OB, Ibeanu OA. Analysis of racial disparities in stage IIIC epithelial ovarian cancer care and outcomes in a tertiary gynecologic oncology referral center. Gynecol Oncol. 2011;122:319–23.

    Article  PubMed  Google Scholar 

  91. Bristow RE, Zahurak ML, Ibeanu OA. Racial disparities in ovarian cancer surgical care: a population-based analysis. Gynecol Oncol. 2011;121:364–8.

    Article  PubMed  Google Scholar 

  92. Terplan M, Smith EJ, Temkin SM. Race in ovarian cancer treatment and survival: a systematic review with meta-analysis. Cancer Causes Control. 2009;20(7):1139–50.

    Article  PubMed  Google Scholar 

  93. Liu FW, Randall LM, Tewari KS, Bristow RE. Racial disparities and patterns of ovarian cancer surgical care in California. Gynecol Oncol. 2014;132(1):221–6.

    Article  CAS  PubMed  Google Scholar 

  94. Terplan M, Schluterman N, McNamara EJ, Tracy JK, Temkin SM. Have racial disparities in ovarian cancer increased over time? An analysis of SEER data. Gynecol Oncol. 2012;125(1):19–24.

    Article  PubMed  Google Scholar 

  95. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11–30.

    Article  PubMed  Google Scholar 

  96. Barnholtz-Sloan JS, Schwartz AG, Qureshi F, Jacques S, Malone J, Munkarah AR. Ovarian cancer: changes in patterns at diagnosis and relative survival over the last three decades. Am J Obstet Gynecol. 2003;189(4):1120–7.

    Article  PubMed  Google Scholar 

  97. Howell EA, Egorova N, Hayes MP, Wisnivesky J, Franco R, Bickell N. Racial disparities in the treatment of advanced epithelial ovarian cancer. Obstet Gynecol. 2013;122(5):1025–32.

    Article  PubMed  Google Scholar 

  98. Long B, Chang J, Ziogas A, Tewari KS, Anton-Culver H, Bristow RE. Impact of race, socioeconomic status, and the health care system on the treatment of advanced-stage ovarian cancer in California. Am J Obstet Gynecol. 2015;212(4):468.e1–9.

    Article  Google Scholar 

  99. Bristow RE, Chang J, Ziogas A, Anton-Culver H, Vieira VM. Spatial analysis of adherence to treatment guidelines for advanced-stage ovarian cancer and the impact of race and socioeconomic status. Gynecol Oncol. 2014;134(1):60–7.

    Article  PubMed  PubMed Central  Google Scholar 

  100. Peterson CE, Rauscher GH, Johnson TP, Kirschner CV, Freels S, Barrett RE, et al. The effect of neighborhood disadvantage on the racial disparity in ovarian cancer-specific survival in a large hospital-based study in cook county, Illinois. Front Publ Health. 2015;3:8.

    Article  Google Scholar 

  101. Bristow RE, Chang J, Ziogas A, Campos B, Chavez LR, Anton-Culver H. Sociodemographic disparities in advanced ovarian cancer survival and adherence to treatment guidelines. Obstet Gynecol. 2015;125(4):833–42.

    Article  PubMed  Google Scholar 

  102. Terplan M, Temkin S, Tergas A, Lengyel E. Does equal treatment yield equal outcomes? The impact of race on survival in epithelial ovarian cancer. Gynecol Oncol. 2008;111(2):173–8.

    Article  PubMed  PubMed Central  Google Scholar 

  103. Du XL, Sun CC, Milam MR, Bodurka DC, Fang S. Ethnic differences in socioeconomic status, diagnosis, treatment, and survival among older women with epithelial ovarian cancer. Int J Gynecol Cancer. 2008;18(4):660–9.

    Article  CAS  PubMed  Google Scholar 

  104. Farley JH, Tian C, Rose GS, Brown CL, Birrer M, Maxwell GL. Race does not impact outcome for advanced ovarian cancer patients treated with cisplatin/paclitaxel: an analysis of Gynecologic Oncology Group trials. Cancer. 2009;115(18):4210–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  105. Albain KS, Unger JM, Crowley JJ, Coltman CA, Hershman DL. Racial disparities in cancer survival among randomized clinical trials patients of the Southwest Oncology Group. J Natl Cancer Inst. 2009;101(14):984–92.

    Article  PubMed  PubMed Central  Google Scholar 

  106. Tergas AI, Tseng JH, Bristow RE. Impact of race and ethnicity on treatment and survival of women with vulvar cancer in the United States. Gynecol Oncol. 2013;129(1):154–8.

    Article  PubMed  Google Scholar 

  107. Rauh-Hain JA, Clemmer J, Clark RM, Bradford LS, Growdon WB, Goodman A, et al. Racial disparities and changes in clinical characteristics and survival for vulvar cancer over time. Am J Obstet Gynecol. 2013;209(5):468.e1–10.

    Article  Google Scholar 

  108. Mahdi H, Kumar S, Hanna RK, Munkarah AR, Lockhart D, Morris RT, et al. Disparities in treatment and survival between African American and White women with vaginal cancer. Gynecol Oncol. 2011;122(1):38–41.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Gyncologic Oncology, Department of Obstetrics and Gynecology, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Ave, Boston, MA, 02215, USA

    Fong W. Liu MD, MPH

  2. Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of California at Irvine, 101 The City Drive, Orange, CA, 92868, USA

    Robert E. Bristow MD, MBA

  3. Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Columbia University Medical Center, 161 Fort Washington Ave, New York, NY, 10011, USA

    Ana I. Tergas MD, MPH

Authors
  1. Fong W. Liu MD, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robert E. Bristow MD, MBA
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ana I. Tergas MD, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Fong W. Liu MD, MPH .

Editor information

Editors and Affiliations

  1. Department of Biology, Temple University, Philadelphia, Pennsylvania, USA

    Antonio Giordano

  2. Department of Biology, Temple University, Philadelphia, Pennsylvania, USA

    Marcella Macaluso

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Liu, F.W., Bristow, R.E., Tergas, A.I. (2016). Racial/Ethnic Disparities in Gynecological Cancer Screening, Treatment, and Survival. In: Giordano, A., Macaluso, M. (eds) Gynecological Cancers. Current Clinical Oncology. Springer, Cham. https://doi.org/10.1007/978-3-319-32907-9_8

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-32907-9_8

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-32905-5

  • Online ISBN: 978-3-319-32907-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation